Navigation Links
Nationwide Survey Reveals Differing Physician and Patient Perceptions Regarding Impact of Ulcerative Colitis on Patients' Lives
Date:12/7/2007

rough acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire's focused strategy is to develop and market products for specialty physicians. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company's website: http://www.shire.com.

For further information please contact:

Media Blythe Bertolo (GolinHarris) +1 312 729 4463

Matthew Cabrey (Shire) +1 484 595 8248

GIULIANI SpA

Giuliani SpA, founded in 1889, is a privately owned specialty pharmaceutical company strategically focused in gastroenterology and dermatology. It is currently marketing proprietary products for the treatment and management of ulcerative colitis, Crohn's disease, food intolerances and dermatological disorders. Giuliani's R&D pipeline includes new chemical entities and biotechnological products targeted to treat inflammatory and autoimmune diseases.

COSMO Pharmaceuticals SpA

Cosmo is a specialty pharmaceutical company that aims to become a global leader in optimized therapies for certain gastrointestinal diseases. The company's proprietary clinical development pipeline specifically addresses innovative treatments for IBD, such as ulcerative colitis and Crohn's disease, and colon infections. Cosmo's most advanced development product is LIALDA(TM)/ MEZAVANT(TM) a treatment for ulcerative colitis that is licensed globally to Giuliani and Shire Pharmaceuticals. Cosmo's proprietary MMX technology is at the core of the company's product pipeline and was developed from its expertise in formulating and manufacturing gastrointestinal drugs for international clients at
'/>"/>

SOURCE Shire PLC
Copyright©2007 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Flu Vaccinations Begin on September 29 Maxim Health Systems to Provide 24,000 Flu Shot Clinics Nationwide
2. Joint NJ/NY Rally for Addiction Recovery to Be Hub of Events Nationwide
3. Photo: Tanger Outlet Center Shoppers Nationwide can Choose Pink to Fight Breast Cancer
4. Joint Juice Launches New Ready-to-Drink Glucosamine & Vitamin-Enhanced Dietary Supplement Water Nationwide
5. Activate America(R) Brings Together YMCAs Nationwide to Promote Small Steps Toward a Healthier Lifestyle During America on the Move Week With the YMCA, September 22-29, 2007
6. NIH/NCI renews and extends nationwide license for Genomatix software and databases
7. 100 Black Men of America, Inc. and American Red Cross Sign National Agreement to Increase Diverse Outreach Nationwide
8. New Website Launches Healthy Vending in Schools Nationwide to Help Combat Childhood Obesity
9. First Nationwide Class Action Filed on Behalf of Consumers Who Purchased Topps E. Coli Contaminated Ground Beef
10. American Cancer Society awards research grants to 109 investigators at 77 institutions nationwide
11. Nationwide independent Taser study results suggest devices are safe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)...nt gene could ease sickle-cell disease and thalass..., 2008 -- Researchers at Children,s Hospital Bosto...ncer Institute have identified a way to get red bl... made only before birth or by young infants. This ...d beta-thalassemia -- life-threatening inherited a...
(Date:12/4/2008)... members can gain access to cutting edge education...ationally-recognized speakers and opportunities fo... be on December 10, 2008: , Finding and Commun... where your online influencers and audiences live?... them? , This webinar will give you the knowle...
(Date:12/4/2008)...n Joffe, Craig Joffe, and,Alan Buckey today filed...,Securities and Exchange Commission. The group pr...% of LCA-Vision, Inc. (Nasdaq: LCAV ), which,op...tion centers in 33 states,in the United States. ...EO of,LCAV. Craig Joffe is the former Chief Oper...
(Date:12/4/2008)...on Healthcare, Inc. reminds,consumers to take ful...,Spending Accounts (FSA,s) before they expire by ...onal and family health such as home blood pressure...://www.newscom.com/cgi-bin/prnh/20081204/AQTH541-a...in/prnh/20081204/AQTH541-b ) , As 2009 heal...
Breaking Medicine News(10 mins):Health News:Turning back the Clock in Inherited Anemias 2Health News:Turning back the Clock in Inherited Anemias 3Health News:Turning back the Clock in Inherited Anemias 4Health News:New NAMC Member Service! Complimentary Webinars for NAMC Members - On Topics You Need to Know! Sign Up Today for This New and Exciting Educational Program! 2Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 2Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 3Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 4Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 5Health News:11.4% Shareholders & Former Executive Management of LCA-Vision Seek Board Representation and Executive Management Positions 6Health News:Maximize Flex Spending Account Funds Before They Expire 2Health News:Maximize Flex Spending Account Funds Before They Expire 3
...UK Parliamentarian Roger Williams has called for a...s used in the production of 6,000 types of medicin...nite evidence that the sweetener, which is used in...e European Ramazzini Foundation has published repo...
...number of people afflicted with the Alzheimer's di...es, greater longevity and the population explosion...eople suffer from dementia which is connected to c...he year 2020, this figure is expected to rise to 4...
...oms for women, produced by the state-owned Hindust...ally in select cities.// 'For the past year we had...oss the country and from the excellent response fr...t is time to enter the market. This would now be a...
... study it has been found that a herbal supplement ...bater is N-acetylcysteine (NAC) which is a potenti...ion.// This has been successfully tried in animal ...oin addiction, and possibly alcoholism. NAC is av...
Other Medicine News:Health News:A herbal drug addiction releiver 2
(Date:12/2/2008)...ire-USNewswire/ -- Researchers using functional,M...e area of the brain,responsible for suppressing m...,stress-related psychiatric disorders. Results of ...eeting of the Radiological Society of North Americ...ssion and other stress-related disorders,traumat...
(Date:12/2/2008)... Biopure Corporation,(N...l Medical Research Center,(NMRC) has submitted to...,investigational new drug (IND) application to con...rapeutic Hemopure(R) [hemoglobin glutamer - 250 (b...t of trauma patients. The study is,entitled "Oper...
(Date:12/2/2008)... TorreyPines Therapeutics, Inc. (N...rom a 26 patient Phase II trial evaluating three d...ry mouth, in patients with Sjogren,s syndrome. NG...ignificant increase in salivary flow production co..., and 20 mg. These doses were safe and well tolera...
(Date:12/2/2008)...RNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: ...el, proprietary antibodies for the treatment of ca...announced that it has entered into an agreement ex...EFF) with Kingsbridge Capital Limited, a private i..., Kingsbridge has committed to provide up to $75 m...
Breaking Medicine Technology:Stress-Related Disorders Affect Brain's Processing of Memory 2Stress-Related Disorders Affect Brain's Processing of Memory 3U.S. Naval Medical Research Center Resubmits IND Application for Proposed 'Op RESUS' Clinical Trial in Trauma Patients in the Battlefield Setting 2U.S. Naval Medical Research Center Resubmits IND Application for Proposed 'Op RESUS' Clinical Trial in Trauma Patients in the Battlefield Setting 3TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 2TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 3TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 4TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 5Micromet Expands Committed Equity Financing Facility to $75 Million 2Micromet Expands Committed Equity Financing Facility to $75 Million 3Micromet Expands Committed Equity Financing Facility to $75 Million 4Micromet Expands Committed Equity Financing Facility to $75 Million 5Micromet Expands Committed Equity Financing Facility to $75 Million 6Caring Give Back A Smile Volunteer Dental Professionals Donate Over 245 Million in Services to Survivors of Domestic Violence 11827 1Caring Give Back A Smile Volunteer Dental Professionals Donate Over 245 Million in Services to Survivors of Domestic Violence 11827 2Great Ape Trust signs agreement with Universitas Nasional in Jakarta 2192 1Great Ape Trust signs agreement with Universitas Nasional in Jakarta 2192 2Great Ape Trust signs agreement with Universitas Nasional in Jakarta 2192 3Great Ape Trust signs agreement with Universitas Nasional in Jakarta 2192 4Great Ape Trust signs agreement with Universitas Nasional in Jakarta 2192 5U of I study 3A exercise to avoid gallstones 21 11822 1U of I study 3A exercise to avoid gallstones 21 11822 2National Council on Disability to Make Recommendations on Youth with Disabilities in the Foster Care System 11819 1National Council on Disability to Make Recommendations on Youth with Disabilities in the Foster Care System 11819 2
...BUSINESS WIRE)--Apr 25, 2007 - BioDelivery,Science...ay,statistically significant results with BEMA(TM)...n in its pivotal Phase III efficacy,clinical trial...ment of the primary efficacy endpoint of the trial...pared to placebo., The results demonstrated that p...
...; April 25, 2007 - Genmab A/S (CSE: GEN),announced...fatumumab (HuMax-CD20™) in patients with rhe... presentation at the 2007,Annual European Congress...hich will include new results from the double-blin...ab, along with data,from the previous interim anal...
Other Medicine Technology:BDSI Announces Positive Phase III Clinical Trial Results for BEMA,Fentanyl 2BDSI Announces Positive Phase III Clinical Trial Results for BEMA,Fentanyl 3BDSI Announces Positive Phase III Clinical Trial Results for BEMA,Fentanyl 4BDSI Announces Positive Phase III Clinical Trial Results for BEMA,Fentanyl 5BDSI Announces Positive Phase III Clinical Trial Results for BEMA,Fentanyl 6
As part of a new modular Endourological Platform concept, the Sonolith Praktis combines the latest technology developped in extracorporeal lithotripsy: electroconductivity, with a compact and innovat
Used for temporary control of male urinary incontinence due to surgery or neurogenic disorder. Supplied non-sterile. Reusable. Intended for single patient use only.
Used for male external catheterization due to urinary incontinence. The inflatable retention ring secures the catheter and can be easily deflated for removal. Supplied non-sterile. Reusable. Intended
The latex free, hydrophilic Self-Cath Plus is designed for single use, intermittent self-catheterization. The unique hydrophilic coating activates immediately upon exposure to water for fast, clean
Medicine Products: